Rankings
▼
Calendar
CRDF Q4 2025 Earnings — Cardiff Oncology, Inc. Revenue & Financial Results | Market Cap Arena
CRDF
Cardiff Oncology, Inc.
$139M
Q4 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$243,000
+60.9% YoY
Gross Profit
$20,000
8.2% margin
Operating Income
-$8M
-3221.0% margin
Net Income
-$7M
-2970.0% margin
EPS (Diluted)
$-0.11
QoQ Revenue Growth
+102.5%
Cash Flow
Operating Cash Flow
-$6M
Free Cash Flow
-$6M
Stock-Based Comp.
$1M
Balance Sheet
Total Assets
$62M
Total Liabilities
$16M
Stockholders' Equity
$45M
Cash & Equivalents
$17M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$243,000
$151,000
+60.9%
Gross Profit
$20,000
$151,000
-86.8%
Operating Income
-$8M
-$13M
+37.7%
Net Income
-$7M
-$12M
+38.8%
← FY 2025
All Quarters